Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
10 2022
Historique:
received: 26 02 2022
revised: 03 05 2022
accepted: 04 05 2022
pubmed: 24 7 2022
medline: 28 9 2022
entrez: 23 7 2022
Statut: ppublish

Résumé

Computerised decision-support systems (CDSSs) for antibiotic stewardship could help to assist physicians in the appropriate prescribing of antibiotics. However, high-quality evidence for their effect on the quantity and quality of antibiotic use remains scarce. The aim of our study was to assess whether a computerised decision support for antimicrobial stewardship combined with feedback on prescribing indicators can reduce antimicrobial prescriptions for adults admitted to hospital. The Computerised Antibiotic Stewardship Study (COMPASS) was a multicentre, cluster-randomised, parallel-group, open-label superiority trial that aimed to assess whether a multimodal computerised antibiotic-stewardship intervention is effective in reducing antibiotic use for adults admitted to hospital. After pairwise matching, 24 wards in three Swiss tertiary-care and secondary-care hospitals were randomised (1:1) to the CDSS intervention or to standard antibiotic stewardship measures using an online random sequence generator. The multimodal intervention consisted of a CDSS providing support for choice, duration, and re-evaluation of antimicrobial therapy, and feedback on antimicrobial prescribing quality. The primary outcome was overall systemic antibiotic use measured in days of therapy per admission, using adjusted-hurdle negative-binomial mixed-effects models. The analysis was done by intention to treat and per protocol. The study was registered with ClinicalTrials.gov (identifier NCT03120975). 24 clusters (16 at Geneva University Hospitals and eight at Ticino Regional Hospitals) were eligible and randomly assigned to control or intervention between Oct 1, 2018, and Dec 31, 2019. Overall, 4578 (40·2%) of 11 384 admissions received antibiotic therapy in the intervention group and 4142 (42·8%) of 9673 in the control group. The unadjusted overall mean days of therapy per admission was slightly lower in the intervention group than in the control group (3·2 days of therapy per admission, SD 6·2, vs 3·5 days of therapy per admission, SD 6·8; p<0·0001), and was similar among patients receiving antibiotics (7·9 days of therapy per admission, SD 7·6, vs 8·1 days of therapy per admission, SD 8·4; p=0·50). After adjusting for confounders, there was no statistically significant difference between groups for the odds of an admission receiving antibiotics (odds ratio [OR] for intervention vs control 1·12, 95% CI 0·94-1·33). For admissions with antibiotic exposure, days of therapy per admission were also similar (incidence rate ratio 0·98, 95% CI 0·90-1·07). Overall, the CDSS was used at least once in 3466 (75·7%) of 4578 admissions with any antibiotic prescription, but from the first day of antibiotic treatment for only 1602 (58·9%) of 2721 admissions in Geneva. For those for whom the CDSS was not used from the first day, mean time to use of CDSS was 8·9 days. Based on the manual review of 1195 randomly selected charts, transition from intravenous to oral therapy was significantly more frequent in the intervention group after adjusting for confounders (154 [76·6%] of 201 vs 187 [87%] of 215, +10·4%; OR 1·9, 95% CI 1·1-3·3). Consultations by infectious disease specialists were less frequent in the intervention group (388 [13·4%] of 2889) versus the control group (405 [16·9%] of 2390; OR 0·84, 95% CI 0·59-1·25). An integrated multimodal computerised antibiotic stewardship intervention did not significantly reduce overall antibiotic use, the primary outcome of the study. Contributing factors were probably insufficient uptake, a setting with relatively low antibiotic use at baseline, and delays between ward admission and first CDSS use. Swiss National Science Foundation. For the French and Italian translations of the abstract see Supplementary Materials section.

Sections du résumé

BACKGROUND
Computerised decision-support systems (CDSSs) for antibiotic stewardship could help to assist physicians in the appropriate prescribing of antibiotics. However, high-quality evidence for their effect on the quantity and quality of antibiotic use remains scarce. The aim of our study was to assess whether a computerised decision support for antimicrobial stewardship combined with feedback on prescribing indicators can reduce antimicrobial prescriptions for adults admitted to hospital.
METHODS
The Computerised Antibiotic Stewardship Study (COMPASS) was a multicentre, cluster-randomised, parallel-group, open-label superiority trial that aimed to assess whether a multimodal computerised antibiotic-stewardship intervention is effective in reducing antibiotic use for adults admitted to hospital. After pairwise matching, 24 wards in three Swiss tertiary-care and secondary-care hospitals were randomised (1:1) to the CDSS intervention or to standard antibiotic stewardship measures using an online random sequence generator. The multimodal intervention consisted of a CDSS providing support for choice, duration, and re-evaluation of antimicrobial therapy, and feedback on antimicrobial prescribing quality. The primary outcome was overall systemic antibiotic use measured in days of therapy per admission, using adjusted-hurdle negative-binomial mixed-effects models. The analysis was done by intention to treat and per protocol. The study was registered with ClinicalTrials.gov (identifier NCT03120975).
FINDINGS
24 clusters (16 at Geneva University Hospitals and eight at Ticino Regional Hospitals) were eligible and randomly assigned to control or intervention between Oct 1, 2018, and Dec 31, 2019. Overall, 4578 (40·2%) of 11 384 admissions received antibiotic therapy in the intervention group and 4142 (42·8%) of 9673 in the control group. The unadjusted overall mean days of therapy per admission was slightly lower in the intervention group than in the control group (3·2 days of therapy per admission, SD 6·2, vs 3·5 days of therapy per admission, SD 6·8; p<0·0001), and was similar among patients receiving antibiotics (7·9 days of therapy per admission, SD 7·6, vs 8·1 days of therapy per admission, SD 8·4; p=0·50). After adjusting for confounders, there was no statistically significant difference between groups for the odds of an admission receiving antibiotics (odds ratio [OR] for intervention vs control 1·12, 95% CI 0·94-1·33). For admissions with antibiotic exposure, days of therapy per admission were also similar (incidence rate ratio 0·98, 95% CI 0·90-1·07). Overall, the CDSS was used at least once in 3466 (75·7%) of 4578 admissions with any antibiotic prescription, but from the first day of antibiotic treatment for only 1602 (58·9%) of 2721 admissions in Geneva. For those for whom the CDSS was not used from the first day, mean time to use of CDSS was 8·9 days. Based on the manual review of 1195 randomly selected charts, transition from intravenous to oral therapy was significantly more frequent in the intervention group after adjusting for confounders (154 [76·6%] of 201 vs 187 [87%] of 215, +10·4%; OR 1·9, 95% CI 1·1-3·3). Consultations by infectious disease specialists were less frequent in the intervention group (388 [13·4%] of 2889) versus the control group (405 [16·9%] of 2390; OR 0·84, 95% CI 0·59-1·25).
INTERPRETATION
An integrated multimodal computerised antibiotic stewardship intervention did not significantly reduce overall antibiotic use, the primary outcome of the study. Contributing factors were probably insufficient uptake, a setting with relatively low antibiotic use at baseline, and delays between ward admission and first CDSS use.
FUNDING
Swiss National Science Foundation.
TRANSLATIONS
For the French and Italian translations of the abstract see Supplementary Materials section.

Identifiants

pubmed: 35870478
pii: S1473-3099(22)00308-5
doi: 10.1016/S1473-3099(22)00308-5
pmc: PMC9491854
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Banques de données

ClinicalTrials.gov
['NCT03120975']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1493-1502

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

J Med Internet Res. 2019 Mar 19;21(3):e11732
pubmed: 30888324
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Antimicrob Resist Infect Control. 2018 Sep 10;7:109
pubmed: 30214718
Antimicrob Resist Infect Control. 2019 Feb 12;8:35
pubmed: 30805182
Clin Microbiol Infect. 2020 Jan;26(1):41-50
pubmed: 31493472
Respir Med. 1998 Aug;92(8):1032-9
pubmed: 9893772
J Antimicrob Chemother. 2017 Oct 1;72(10):2910-2914
pubmed: 29091207
Stud Health Technol Inform. 2019 Jul 4;262:138-141
pubmed: 31349285
Clin Microbiol Infect. 2019 May;25(5):555-561
pubmed: 30472426
Clin Microbiol Infect. 2017 Nov;23(11):793-798
pubmed: 28882725
BMJ Open. 2018 Jun 27;8(6):e022666
pubmed: 29950480
Clin Infect Dis. 2017 Feb 1;64(3):377-383
pubmed: 27927866
Lancet Reg Health Eur. 2021 Jun 29;7:100161
pubmed: 34557847
Clin Microbiol Infect. 2017 Nov;23(11):799-805
pubmed: 28750920
Lancet Infect Dis. 2017 Sep;17(9):990-1001
pubmed: 28629876
Clin Microbiol Infect. 2017 Nov;23(11):819-825
pubmed: 28571767
Clin Microbiol Infect. 2019 Feb;25(2):163-168
pubmed: 30195471
Int J Med Inform. 2017 Oct;106:1-8
pubmed: 28870378
JAMA Intern Med. 2021 Sep 1;181(9):1174-1182
pubmed: 34251396
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Implement Sci. 2007 Nov 30;2:40
pubmed: 18053122
Front Digit Health. 2021 Feb 16;2:583390
pubmed: 34713055
Antimicrob Resist Infect Control. 2020 Jul 21;9(1):114
pubmed: 32693826
Health Informatics J. 2021 Apr-Jun;27(2):14604582211007536
pubmed: 33853395
Int J Med Inform. 2016 Aug;92:15-34
pubmed: 27318068
Int J Antimicrob Agents. 2020 Jan;55(1):105769
pubmed: 31362046
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Infect Control Hosp Epidemiol. 2019 Oct;40(10):1170-1175
pubmed: 31407651
Int J Antimicrob Agents. 2015 Mar;45(3):203-12
pubmed: 25630430

Auteurs

Gaud Catho (G)

Division of Infectious Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: gaud.catho@hcuge.ch.

Julien Sauser (J)

Division of Infection Control, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Valentina Coray (V)

Division of Clinical Informatics, Ente Ospdaliero Cantonale, Bellinzona, Switzerland.

Serge Da Silva (S)

Division of Informatics, Geneva University Hospital, Geneva, Switzerland.

Luigia Elzi (L)

Division of Infectious Diseases, Ospedale San Giovanni, Ente Ospdaliero Cantonale, Bellinzona, Switzerland.

Stephan Harbarth (S)

Division of Infectious Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland; Division of Infection Control, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Laurent Kaiser (L)

Division of Infectious Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Christophe Marti (C)

Division of Internal Medicine, Geneva University Hospital, Geneva, Switzerland.

Rodolphe Meyer (R)

Division of Informatics, Geneva University Hospital, Geneva, Switzerland.

Francesco Pagnamenta (F)

Division of Clinical Informatics, Ente Ospdaliero Cantonale, Bellinzona, Switzerland.

Javier Portela (J)

Division of Informatics, Geneva University Hospital, Geneva, Switzerland.

Virginie Prendki (V)

Division of Geriatrics, Geneva University Hospital, Geneva, Switzerland.

Alice Ranzani (A)

Division of Infectious Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Nicolò Saverio Centemero (NS)

Division of Clinical Informatics, Ente Ospdaliero Cantonale, Bellinzona, Switzerland.

Jerome Stirnemann (J)

Division of Internal Medicine, Geneva University Hospital, Geneva, Switzerland.

Roberta Valotti (R)

Division of Infectious Diseases, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale and University of Southern Switzerland, Lugano, Switzerland.

Nathalie Vernaz (N)

Medical Directorate, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Brigitte Waldispuehl Suter (BW)

Division of Clinical Informatics, Ente Ospdaliero Cantonale, Bellinzona, Switzerland.

Enos Bernasconi (E)

Division of Infectious Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland; Division of Infectious Diseases, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale and University of Southern Switzerland, Lugano, Switzerland.

Benedikt D Huttner (BD)

Division of Infectious Diseases, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH